Eli Lilly reports Foundayo data and Berenberg rates Eli Lilly stock Buy

Published on 10/05/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 22.97 billion, up 47.70 percent year over year. Eli Lilly stock costs EUR 1,020.20 on October 5, 2026 after EUR 1,016.60.

Bauhaus-Poster mit geometrischen Formen und dem Wort PHARMA in Rot und Blau — Bauhaus-Poster mit geometrischen Formen repräsentiert Eli Lilly and Company, ISIN US5324571083, im Pharmasektor gestalterisch, Illustration mit AI erstellt.

Eli Lilly and Company (ISIN US5324571083) was trading at EUR 1,020.20 at Lang & Schwarz on October 5, 2026 at 12:17 p.m. CEST, up 0.35 percent versus the prior close of EUR 1,016.60. On October 1, 2026, Eli Lilly listed new Foundayo data, while MarketBeat reported on September 15, 2026, that Berenberg rated the stock Buy and set a USD 1,400.00 target.

Foundayo expands the pipeline

The October 1 update followed September 30 clinical data showing cardiovascular safety, sustained A1C reduction and weight loss for Foundayo, Lilly's oral GLP-1 candidate, according to the company's investor page. A separate September 30 update said the EloraTZP combination delivered greater weight loss and A1C reduction than tirzepatide 15 mg in adults with obesity and type 2 diabetes.

For Lilly, these developments widen the growth story beyond Mounjaro and Zepbound. The next earnings call is scheduled for October 29, 2026 at 10:00 a.m. EDT, according to Eli Lilly.

Q2 revenue reached USD 22.97 billion

In the second quarter of 2026, Lilly reported non-GAAP earnings per share of USD 8.38, versus consensus of USD 6.58, while revenue reached USD 22.97 billion, according to AlphaStreet. Revenue increased 47.70 percent year over year, and worldwide Mounjaro revenue rose 91.00 percent to USD 9.94 billion in the same quarter.

Management raised full-year 2026 revenue guidance to USD 85.0 billion to USD 87.0 billion from USD 82.0 billion to USD 85.0 billion. The midpoint therefore increased from USD 83.5 billion to USD 86.0 billion, a rise of 3.00 percent.

Euro quote stays below the dollar high

On the NYSE, LLY was last at USD 1,142.85 on October 2, 2026 at 4:00 p.m. EDT. The primary-exchange market capitalization was USD 1,076.3 billion on October 2, 2026, with a 52-week range of USD 783.85 to USD 1,292.65.

The Lang & Schwarz quote places the German-market reference below the company's recent dollar high, while the October 29 earnings date gives the pipeline updates a defined financial checkpoint. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.